Clinical Trials
3
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery
- Conditions
- Acute Kidney InjuryCardiac Surgery
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- Arch Biopartners Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT05879432
- Locations
- 🇨🇦
University Health Network, Toronto General Hospital, Toronto, Ontario, Canada
🇨🇦Cumming School of Medicine & Libin Cardiovascular Centre, University of Calgary, Calgary, Alberta, Canada
🇨🇦Unity Health Toronto, St. Michael's Hospital, Toronto, Ontario, Canada
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
- Conditions
- Acute Respiratory Distress SyndromeAcute Kidney InjuryCOVIDSevere Acute Respiratory SyndromeSars-CoV2
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Arch Biopartners Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT04402957
- Locations
- 🇺🇸
VA San Diego Healthcare System, San Diego, California, United States
🇺🇸Broward Health Medical Center, Fort Lauderdale, Florida, United States
🇺🇸LSU Health Shreveport, Shreveport, Louisiana, United States
A Phase I Study to Evaluate LSALT Peptide
- Conditions
- None - Study is to Determine Safety in Healthy Participants
- Interventions
- Other: 0.9% Saline
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Arch Biopartners Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT03772678
- Locations
- 🇦🇺
Nucleus Network Ltd., Melbourne, Victoria, Australia
News
Arch Biopartners Establishes Australian Subsidiary for Metablok Phase I Trial in Acute Kidney Injury
Arch Biopartners has created Arch Clinical Pty Ltd in Australia to facilitate a Phase I safety trial for Metablok, a drug candidate targeting acute kidney injury.
Arch Biopartners Initiates Phase II Trial of LSALT Peptide for Cardiac Surgery-Associated Acute Kidney Injury
Arch Biopartners has commenced a Phase II clinical trial of LSALT peptide for preventing and treating cardiac surgery-associated acute kidney injury (CS-AKI).